WEST PHARMACEUTICAL SERVICES (WST) Stock Analyst Ratings
USA - NYSE:WST - US9553061055 - Common Stock
282.02 USD
+3.48 (+1.25%)
ChartMill assigns a Buy % Consensus number of 81% to WST. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 352.25. This target is 24.9% above the current price.
WST was analyzed by 20 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about WST.
In the previous month the buy percentage consensus was at a similar level.
WST was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | TD Cowen | Initiate | Buy |
| 2025-10-27 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-24 | UBS | Maintains | Buy -> Buy |
| 2025-10-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-15 | Rothschild & Co | Initiate | Buy |
| 2025-07-25 | UBS | Maintains | Buy -> Buy |
| 2025-07-25 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-06-24 | Barclays | Initiate | Equal-Weight |
| 2025-03-18 | Evercore ISI Group | Initiate | Outperform |
| 2025-02-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-01-08 | Citigroup | Initiate | Buy |
| 2024-12-13 | Wolfe Research | Initiate | Peer Perform |
| 2024-12-13 | B of A Securities | Maintains | Buy -> Buy |
| 2024-12-12 | UBS | Upgrade | Neutral -> Buy |
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-07 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-27 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-08-30 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-08-21 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-28 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-06-16 | B of A Securities | Upgrade | Neutral -> Buy |
| 2023-04-11 | Stephens & Co. | Upgrade | Equal-Weight -> Overweight |
| 2023-02-17 | Keybanc | Maintains | Overweight |
| 2022-12-14 | Deutsche Bank | Initiate | Hold |
| 2022-12-02 | Keybanc | Maintains | Overweight |
| 2022-11-30 | UBS | Initiate | Neutral |
WEST PHARMACEUTICAL SERVICES / WST FAQ
What is the price target for WST stock?
20 analysts have analysed WST and the average price target is 352.25 USD. This implies a price increase of 24.9% is expected in the next year compared to the current price of 282.02.
How do analysts rate WEST PHARMACEUTICAL SERVICES (WST)?
The consensus rating for WEST PHARMACEUTICAL SERVICES (WST) is 81 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for WST stock?
The number of analysts covering WEST PHARMACEUTICAL SERVICES (WST) is 20.